Alto’s Neuropsychiatric Platform Scores Third Mid-Stage Win

Alto Neuroscience on Monday announced that its candidate ALTO-300 met its primary endpoint in a Phase IIa major depressive disorder trial, inducing significant symptomatic improvement in patients bearing a specific electroencephalogram-based biomarker.